Table 7.
Univariate analysis of elevated pancreatic enzymes in COVID-19 patients (n = 52).
| Influence factors | Group | Elevated (n = 29) | Without elevated (n = 23) | P |
|---|---|---|---|---|
| Age | ≥60 | 19 | 15 | 0.174 |
| <60 | 10 | 8 | ||
| Sex | 1 | 18 | 17 | 0.368 |
| 0 | 11 | 6 | ||
| Smoking history | 1 | 2 | 7 | 0.079 |
| 0 | 27 | 16 | ||
| Drinking history | 1 | 1 | 4 | 0.125 |
| 0 | 28 | 19 | ||
| Hypertension | 1 | 13 | 9 | 0.68 |
| 0 | 16 | 14 | ||
| Diabetes | 1 | 6 | 4 | 0.785 |
| 0 | 23 | 19 | ||
| COPD | 1 | 0 | 0 | - |
| 0 | 29 | 23 | ||
| Chronic nephrosis | 1 | 1 | 2 | 0.436 |
| 0 | 28 | 21 | ||
| Carcinoma | 1 | 1 | 3 | 0.228 |
| 0 | 28 | 20 | ||
| Hyperlipidemia | 1 | 0 | 0 | - |
| 0 | 29 | 23 | ||
| HCV | 1 | 0 | 0 | - |
| 0 | 29 | 23 | ||
| HBV | 1 | 0 | 0 | - |
| 0 | 29 | 23 | ||
| Fatty liver | 1 | 7 | 7 | 0.612 |
| 0 | 22 | 16 | ||
| Gallstone | 1 | 4 | 6 | 0.271 |
| 0 | 25 | 17 | ||
| Cholestasis | 1 | 6 | 1 | 0.119 |
| 0 | 23 | 22 | ||
| Mechanical ventilation | 1 | 21 | 7 | 0.004 |
| 0 | 8 | 16 | ||
| Shock | 1 | 5 | 1 | 0.180 |
| 0 | 24 | 22 | ||
| Kidney injury | 1 | 13 | 4 | 0.042 |
| 0 | 16 | 19 |
HBV, hepatitis B virus; HCV, hepatitis C virus.